Immupharma Share Discussion Threads

[englishlongbow] 01/12/2017 15:26

Provides a bargain price buying opportunity for the rest of us. Thanks.

[topdiesel] 01/12/2017 15:22

I think you will see a large sell order filled at the end of today or tomorrow. The pattern has been consistent lately with some big boy(s) top slicing or hedging their bets. I would guess the most recent one will close tomorrow end of day showing a sell at 124 or 125. Once all of the sells in the hundreds of thousands at this level taper off it seems to jump to the next level. DYOR

[hamhamham1] 01/12/2017 15:20

ahhh - cheers - its my end then not the general market.

[greedfear] 01/12/2017 15:19

No problem selling 10,000 @123.47

[hamhamham1] 01/12/2017 15:15

I can't see any buyers out there?
(when I try to sell - no offers to buy my shares at any price - buyers only for up to about 80 shares but no more?)
Does anyone have more visibility?

[alphatim] 01/12/2017 15:03

Could well be an interesting trial update next week. Any numbers released now, though, would give clues as to drop-out rate. The Company may wish to withhold this information until last patient dosed/out so as to avoid any, however small, uncontrolled effect on the final patient results.
As a thought, would the trial end earlier than scheduled if the last few patients to be dosed had already dropped out throughout the year...?

[hamhamham1] 01/12/2017 12:54

dyslexia :) 127.25-127.50

[hamhamham1] 01/12/2017 12:53

172.25-172.50 - tightest i seen it - could go up now

[alphapig] 01/12/2017 12:46

A few buys not showing yet, bid creeping up!

[ny boy] 01/12/2017 12:23

blackbear

This one is going to be a monster trade, so far so good, fever pitch by the New Year but happy I’d we make 150-175p band by then, that's before any phase 3 trial announcements


Are you in Blockchain plays (BLU) & (VELA)? early days but reminds me of Apple etc when they were off the radar and just a two bit $ stock. Dyor as usual

[l0ngterm] 01/12/2017 11:51

In addendum Immupharma have a patent for enhancing peptides to be taken orally, lupuzor is currently subcutaneously.https://www.google.com.pg/patents/US6908900

[l0ngterm] 01/12/2017 11:39

Can also be extended for:New uses (could be any of the above)Stereoselectivity ( method of administration changing)New formulationsCombinationshttp://www.biopharminternational.com/strategies-extending-life-patents?pageID=3

[postbrexit1] 01/12/2017 11:37

Indiv just got FDA approval. Up 30p. From 246 to 410 in a year. Imagine imm, when the time comes!

[l0ngterm] 01/12/2017 11:31

Can be + 7 years exclusivity from the fda for treatments that orphan status. I believe sjorns falls into this category. Note: this can run parallel to patent. https://www.fda.gov/downloads/drugs/developmentapprovalprocess/smallbusinessassistance/ucm447307.pdf

[che7win] 01/12/2017 10:51

So that's a 20 year patent or so for exploitation?

[w1ndjammer] 01/12/2017 10:47

you only need to see what happened over at PYC not a holder, but was on my watch list
so someone must have given me the tip. 20 bagger in a couple of days.

The same will happen here in the not to distant future.

WJ.

[ballsac] 01/12/2017 10:44

There seems to be an increasing awareness that Lupuzor P140 could already be worth £200 a share, as it could treat at least 14 indications not just SLE, supporting the Holy Grail of pharmas "several blockbusters in one" school of thought:

- Systemic Lupus Erythematosus (SLE) (Market size $4 bn)
- Neuropsychiatric lupus (NPSLE)
- Rheumatoid Arthritis / Juvenile Arthritis (Market size $28.5 bn by 2025)
- Sjogren's Syndrome (Market size $2.2 bn by 2024)
- Crohn's Disease + Ulcerative Colitis (Market size $4 bn by 2022)
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Guillan-Barre syndrome (Market size $520m in 2017)
- Multiple Sclerosis (MS) (Market size $20 bn by 2024)
- Insulin Dependent Diabetes (Market size $43 bn by 2021)
- Bullous Diseases (Market size $1.6 bn for Bullous Pemphigoid)
- Mixed Connective Tissue Disease
- Asthma
- Scleroderma (Systemic Sclerosis, Raynaud)
- Psoriasis

IMM have a new Lupuzor patent (granted 2017) covering key markets (USA, EU, China, India & Japan) to 2032 & use in the majority of autoimmune indications. A new patent has also been filed to cover non-autoimmune indications. (IMM, Sep 2017)

[che7win] 01/12/2017 10:36

150p coming next, going to be interesting coming up to results!

[qazwsxedc69] 01/12/2017 10:17

Remarkosick wanders around ADFVN boards like a drunk tramp wandering around a train station at night, can of cider in hand, shouting random words at people who don't listen to him.

[ny boy] 01/12/2017 10:16

As expected buys from earlier starting to show MM’s play the spread, knock out weak holders, the price moves up, too many want into the big game changer story end of Jan onwards, most are hoovering up stock at playing the big gamble, albeit a calculated gamble, based on evidence released from the Company to date. Heading for 150p + this month.

Tick tock

[glennrcharles] 01/12/2017 10:10

Haha Alphapig. .. love it

[alphapig] 01/12/2017 10:09

Glenn, give your shares to loved ones before results, for Xmas, and if results good, take 'em back and buy em socks. Gotta love Christmas.

[alphapig] 01/12/2017 10:06

Remarkomsoc, how's it doing at the mo?